Synthetic glucagon antagonists and partial agonists

CHRISTIAN ZECHEL, DEV TRIVEDI, VICTOR J. HRUBY

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

This paper reports the synthesis and the biological activities of six new glucagon analogues. In these compounds N‐terminal modifications of the glucagon sequence were made, in most cases combined with changes in the C‐terminal region which had been shown previously to enhance receptor affinity. The design of these analogues was based on [Lys17.18,Glu21]glucagon,1 a superagonist, which binds five times better than glucagon to the glucagon receptor, and on the potent glucagon antagonist [d‐Phe4,Tyr5,Arg12]glucagon, which does not stimulate adenylate cyclase system even at very high concentrations. The N‐terminal modifications involved substitution of His1 by the unnatural conformationally constrained residue, 4,5,6,7‐tetrahydro‐1H‐imidazo[c]pyridine‐6‐carboxylic acid (Tip) and by desaminohistidine (dHis). In addition we prepared two analogues (6 and 7), in which we deleted the Phe6 residue, which was suggested to be part of a hydrophobic patch and involved in receptor binding. The following compounds were synthesized: [Tip1, Lys17.18,Glu21]glucagon (2); [Tip1,d‐Phe4,Tyr5,Arg12,Lys17.18,Glu21 glucagon (3); [dHis1,d‐Phe4,Tyr5,Arg12, Lys17.18,Glu21 glucagon (4); [dHis1,Asp3,d‐Phe4,Tyr5,Arg12,Lys17.18,Glu21]glucagon (5); des‐Phe6‐[Tip1,D‐Phe4,Tyr5Arg12,Glu21 glucagon (6); des‐Phe6‐[Asp3,d‐Phe4,Tyr5,Arg12,Glu21]glucagon (7) The binding potencies of these new analogues relative to glucagon (= 100) are 3.2 (2), 2.9 (3), 10.0 (4), 1.0 (5), 8.5 (6), and 1.7 (7). Analogue 2 is a partial agonist (maximum stimulation of adenylate cyclase (AC) approximately 15% and a potency 8.9% that of glucagon, while the remaining compounds 3‐7 are antagonists unable to activate the AC system even at concentrations as high as 10−5m. In addition, in competition experiments, analogues 3‐7 caused a right‐shift of the glucagon stimulated adenylate cyclase dose‐response curve. Hence these compounds are glucagon receptor antagonists with respect to the glucagon receptor coupled to the adenylate cyclase system.

Original languageEnglish (US)
Pages (from-to)131-138
Number of pages8
JournalInternational journal of peptide and protein research
Volume38
Issue number2
DOIs
StatePublished - Aug 1991

Keywords

  • conformational constraint
  • glucagon analogues
  • glucagon antagonists
  • structure activity relationships
  • unusual amino acids

ASJC Scopus subject areas

  • Biochemistry

Fingerprint

Dive into the research topics of 'Synthetic glucagon antagonists and partial agonists'. Together they form a unique fingerprint.

Cite this